• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Accuracy of HbA1c as Monitored by External Quality Assessment and Compared With Patient Mean Values.通过外部质量评估监测的糖化血红蛋白(HbA1c)准确性及其与患者平均值的比较。
J Diabetes Sci Technol. 2018 Jul;12(4):771-779. doi: 10.1177/1932296818785622. Epub 2018 Jun 19.
2
Trueness assessment of HbA1c routine assays: are processed EQA materials up to the job?糖化血红蛋白常规检测方法的准确度评估:处理后的室间质评材料能否胜任这项工作?
Clin Chem Lab Med. 2019 Sep 25;57(10):1623-1631. doi: 10.1515/cclm-2019-0219.
3
Evaluation of Performance of Laboratories and Manufacturers Within the Framework of the IFCC model for Quality Targets of HbA1c.在国际临床化学和检验医学联合会(IFCC)糖化血红蛋白(HbA1c)质量目标模型框架内对实验室和制造商性能的评估。
J Diabetes Sci Technol. 2018 Jul;12(4):747-752. doi: 10.1177/1932296817741320. Epub 2017 Nov 17.
4
Availability and analytical quality of hemoglobin A1c point-of-care testing in general practitioners' offices are associated with better glycemic control in type 2 diabetes.在全科医生办公室中,糖化血红蛋白即时检测的可用性和分析质量与 2 型糖尿病患者的血糖控制改善相关。
Clin Chem Lab Med. 2020 Jul 28;58(8):1349-1356. doi: 10.1515/cclm-2020-0026.
5
Setting analytical performance specifications using HbA1c as a model measurand.使用糖化血红蛋白作为模型指标设置分析性能规格。
Clin Chim Acta. 2021 Dec;523:407-414. doi: 10.1016/j.cca.2021.10.016. Epub 2021 Oct 16.
6
External quality assessment of HbA1c and its effect on comparison between Swedish pediatric diabetes clinics. Experiences from the Swedish pediatric diabetes quality register (Swediabkids) and Equalis.糖化血红蛋白的外部质量评估及其对瑞典儿科糖尿病诊所间比较的影响。来自瑞典儿科糖尿病质量登记处(Swediabkids)和 Equalis 的经验。
Clin Chem Lab Med. 2013 Oct;51(10):2045-52. doi: 10.1515/cclm-2013-0226.
7
Report on HbA1c Proficiency Testing in Asia in 2012.2012年亚洲糖化血红蛋白(HbA1c)能力验证报告。
Ann Lab Med. 2015 May;35(3):352-5. doi: 10.3343/alm.2015.35.3.352. Epub 2015 Apr 1.
8
Retrospective analysis of 55,769 HbA1c EQA results obtained from professional laboratories and medical offices participating in surveys organized by two European EQA centers over a nine-year period.对参与两个欧洲外部质量评估(EQA)中心组织的调查的专业实验室和医疗办公室的 55769 份 HbA1c EQA 结果进行回顾性分析,历时九年。
J Clin Lab Anal. 2011;25(5):337-43. doi: 10.1002/jcla.20482.
9
The Nanjing Glycated Hemoglobin Standardization Program: 2012 to 2015.
Clin Ther. 2017 Jan;39(1):220-229. doi: 10.1016/j.clinthera.2016.11.013. Epub 2016 Dec 3.
10
Application of biological variation and sigma metrics to evaluate the performance of HbA in external quality assessment.应用生物学变异和西格玛度量指标评估 HbA 在室间质量评价中的性能。
Scand J Clin Lab Invest. 2022 Sep;82(5):398-403. doi: 10.1080/00365513.2022.2100822. Epub 2022 Jul 23.

引用本文的文献

1
Development of commutable stabilizing control materials to improve external quality assessment of hemoglobin assay.可互换稳定对照材料的研制,以改善血红蛋白检测的室间质量评价。
Anal Bioanal Chem. 2025 Sep;417(22):5001-5017. doi: 10.1007/s00216-025-06018-4. Epub 2025 Jul 30.
2
Determinants of growth differentiation factor 15 plasma levels in outpatients with peripheral arterial disease.外周动脉疾病门诊患者血浆生长分化因子15水平的决定因素
Ups J Med Sci. 2024 Dec 23;129. doi: 10.48101/ujms.v129.11001. eCollection 2024.
3
Prevalence and risk factors for diabetic retinopathy at diagnosis of type 2 diabetes: an observational study of 77 681 patients from the Swedish National Diabetes Registry.2 型糖尿病诊断时糖尿病视网膜病变的患病率及相关危险因素:来自瑞典国家糖尿病登记处的一项 77681 例患者的观察性研究。
BMJ Open Diabetes Res Care. 2024 Jun 4;12(3):e003976. doi: 10.1136/bmjdrc-2023-003976.
4
Are the results from a multiplex proteomic assay and a conventional immunoassay for NT-proBNP and GDF-15 comparable?用于检测N末端B型利钠肽原(NT-proBNP)和生长分化因子15(GDF-15)的多重蛋白质组学检测与传统免疫检测的结果具有可比性吗?
Clin Proteomics. 2023 Jan 24;20(1):5. doi: 10.1186/s12014-023-09393-1.
5
Neurodevelopmental Disorders, Glycemic Control, and Diabetic Complications in Type 1 Diabetes: a Nationwide Cohort Study.1 型糖尿病的神经发育障碍、血糖控制和糖尿病并发症:一项全国性队列研究。
J Clin Endocrinol Metab. 2021 Oct 21;106(11):e4459-e4470. doi: 10.1210/clinem/dgab467.
6
Poor glycaemic control is associated with increased risk of neurodevelopmental disorders in childhood-onset type 1 diabetes: a population-based cohort study.血糖控制不佳与儿童期起病 1 型糖尿病患者神经发育障碍风险增加相关:一项基于人群的队列研究。
Diabetologia. 2021 Apr;64(4):767-777. doi: 10.1007/s00125-020-05372-5. Epub 2021 Jan 16.
7
A Patient-Level Model to Estimate Lifetime Health Outcomes of Patients With Type 1 Diabetes.一种用于估计 1 型糖尿病患者终生健康结局的患者水平模型。
Diabetes Care. 2020 Aug;43(8):1741-1749. doi: 10.2337/dc19-2249. Epub 2020 Jun 12.
8
Improved metabolic control using glucose monitoring systems leads to improvement in vibration perception thresholds in type 1 diabetes patients.使用血糖监测系统改善代谢控制可改善 1 型糖尿病患者的振动感觉阈值。
Acta Diabetol. 2020 Apr;57(4):433-438. doi: 10.1007/s00592-019-01450-2. Epub 2019 Nov 8.
9
HbA level as a risk factor for retinopathy and nephropathy in children and adults with type 1 diabetes: Swedish population based cohort study.1 型糖尿病儿童和成人的 HbA 水平与视网膜病变和肾病的风险因素:瑞典基于人群的队列研究。
BMJ. 2019 Aug 28;366:l4894. doi: 10.1136/bmj.l4894.
10
Glycaemic control trends in people with type 1 diabetes in Scotland 2004-2016.2004-2016 年苏格兰 1 型糖尿病患者血糖控制趋势。
Diabetologia. 2019 Aug;62(8):1375-1384. doi: 10.1007/s00125-019-4900-7. Epub 2019 May 18.

本文引用的文献

1
EurA1c: The European HbA1c Trial to Investigate the Performance of HbA1c Assays in 2166 Laboratories across 17 Countries and 24 Manufacturers by Use of the IFCC Model for Quality Targets.EurA1c:欧洲 HbA1c 试验,旨在使用 IFCC 质量目标模型,在 17 个国家的 24 家制造商的 2166 家实验室中,调查 HbA1c 检测方法的性能。
Clin Chem. 2018 Aug;64(8):1183-1192. doi: 10.1373/clinchem.2018.288795. Epub 2018 Jun 19.
2
Letter to the Editor regarding "Achieving comparability with IFCC reference method for the measurement of hemoglobin A by use of an improved isotope-dilution mass spectrometry method".
Anal Bioanal Chem. 2017 Sep;409(24):5789-5790. doi: 10.1007/s00216-017-0513-5. Epub 2017 Aug 3.
3
HbA1c: EQA in Germany, Belgium and the Netherlands using fresh whole blood samples with target values assigned with the IFCC reference system.糖化血红蛋白(HbA1c):德国、比利时和荷兰使用新鲜全血样本进行的室间质量评价,目标值依据国际临床化学和检验医学联合会(IFCC)参考系统设定。
Clin Chem Lab Med. 2016 Nov 1;54(11):1769-1775. doi: 10.1515/cclm-2016-0123.
4
Performance of glycated hemoglobin (HbA(1c)) methods evaluated with EQAS studies using fresh blood samples: Still space for improvements.
Clin Chim Acta. 2015 Dec 7;451(Pt B):305-9. doi: 10.1016/j.cca.2015.10.014. Epub 2015 Oct 22.
5
Investigation of 2 models to set and evaluate quality targets for hb a1c: biological variation and sigma-metrics.两种用于设定和评估糖化血红蛋白(HbA1c)质量目标的模型研究:生物学变异和西格玛度量
Clin Chem. 2015 May;61(5):752-9. doi: 10.1373/clinchem.2014.235333. Epub 2015 Mar 3.
6
Assessing quality on the Sigma scale from proficiency testing and external quality assessment surveys.根据能力验证和外部质量评估调查,在西格玛量表上评估质量。
Clin Chem Lab Med. 2015 Sep 1;53(10):1531-5. doi: 10.1515/cclm-2014-1241.
7
Comparison of IFCC-calibrated HbA(1c) from laboratory and point of care testing systems.IFCC 校准的实验室和即时检测系统的 HbA(1c)比较。
Diabetes Res Clin Pract. 2014 Sep;105(3):364-72. doi: 10.1016/j.diabres.2014.05.003. Epub 2014 May 23.
8
External quality assessment of HbA1c and its effect on comparison between Swedish pediatric diabetes clinics. Experiences from the Swedish pediatric diabetes quality register (Swediabkids) and Equalis.糖化血红蛋白的外部质量评估及其对瑞典儿科糖尿病诊所间比较的影响。来自瑞典儿科糖尿病质量登记处(Swediabkids)和 Equalis 的经验。
Clin Chem Lab Med. 2013 Oct;51(10):2045-52. doi: 10.1515/cclm-2013-0226.
9
Coefficient of variation for hemoglobin A1c results that are traceable to national glycohemoglobin standardization program must be distinguished from coefficient of variation for results traceable to International Federation of Clinical Chemistry and Laboratory Medicine.可溯源至国家糖化血红蛋白标准化计划的糖化血红蛋白A1c结果的变异系数,必须与可溯源至国际临床化学和检验医学联合会的结果的变异系数区分开来。
Diabetes Technol Ther. 2011 Dec;13(12):1271-2. doi: 10.1089/dia.2011.0106. Epub 2011 Aug 9.
10
The IFCC Reference Measurement System for HbA1c: a 6-year progress report.国际临床化学和检验医学联合会(IFCC)糖化血红蛋白(HbA1c)参考测量系统:六年进展报告
Clin Chem. 2008 Feb;54(2):240-8. doi: 10.1373/clinchem.2007.097402.

通过外部质量评估监测的糖化血红蛋白(HbA1c)准确性及其与患者平均值的比较。

Accuracy of HbA1c as Monitored by External Quality Assessment and Compared With Patient Mean Values.

作者信息

Nordin Gunnar

机构信息

1 Equalis, Uppsala, Sweden.

出版信息

J Diabetes Sci Technol. 2018 Jul;12(4):771-779. doi: 10.1177/1932296818785622. Epub 2018 Jun 19.

DOI:10.1177/1932296818785622
PMID:29916732
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6134316/
Abstract

BACKGROUND

The accuracy and trueness of results from a laboratory test, such as the HbA1c test, should not be taken for granted but must be checked continuously. A tool for this is the participation in external quality assessment (EQA) for all laboratories performing the HbA1c-test. An additional possibility to detect changes in trueness is to monitor variations in patient cohort mean or median values that is not explained by changes in treatment or selection of patients.

METHODS

Results reported to an EQA scheme for HbA1c during 20 years have been extracted from Equalis database. The results are compared to current analytical performance specifications (APS) and to the mean HbA1c levels for the Swedish population of persons with type 2 diabetes.

RESULTS

The accuracy of the HbA1c test has improved during the period. The hospital lab methods used in Sweden now fulfil APS agreed by professional organizations in Sweden. The accuracy for point-of-care tests (POCT) methods vary over time and fulfil APS for some periods. The bias found for some of the methods might explain changes seen in patient mean values for HbA1c in Sweden during the period 2007-2017.

CONCLUSIONS

The global standardization of HbA1c has resulted in an improved comparability for HbA1c-results worldwide. But even small variation in trueness for the methods in use might have important impact on mean HbA1c values for cohorts of patients. When a systematic error is observed for a specific method it is therefore essential that manufacturers correct the method without delay.

摘要

背景

实验室检测结果的准确性和真实性,如糖化血红蛋白(HbA1c)检测结果,不应被视为理所当然,而必须持续进行核查。对于所有开展HbA1c检测的实验室而言,参与外部质量评估(EQA)是实现这一目的的一种手段。另一种检测真实性变化的可能性是监测患者队列均值或中位数的变化,这种变化无法用治疗或患者选择的改变来解释。

方法

从Equalis数据库中提取了20年间上报至一项HbA1c EQA计划的结果。将这些结果与当前的分析性能规范(APS)以及瑞典2型糖尿病患者群体的HbA1c平均水平进行比较。

结果

在此期间,HbA1c检测的准确性有所提高。瑞典目前使用的医院实验室方法符合瑞典专业组织认可的APS。即时检测(POCT)方法的准确性随时间变化,在某些时期符合APS。部分方法中发现的偏差可能解释了2007 - 2017年期间瑞典HbA1c患者均值中出现的变化。

结论

HbA1c的全球标准化提高了全球范围内HbA1c结果的可比性。但即使是所用方法在真实性上的微小差异,也可能对患者队列的HbA1c均值产生重要影响。因此,当观察到某一特定方法存在系统误差时,制造商必须立即对该方法进行修正。